COMMUNIQUÉ DE PRESSE publié le 24/01/2024 à 14:00, il y a 1 année 10 mois AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement AiCuris and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to discover new active agents for the treatment and prophylaxis of infections of immunocompromised patients. The partnership aims to develop novel therapies for patients with high medical need. The financial details of the collaboration were not disclosed. For more information, visit www.dzif.de and www.aicuris.com. AiCuris German Center For Infection Research Collaboration License Option Agreement Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 28/09/2023 à 14:00, il y a 2 années 2 mois AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 23/08/2023 à 14:00, il y a 2 années 3 mois AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 14:00, il y a 2 années 4 mois AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 14:00, il y a 2 années 8 mois AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary
Publié le 04/12/2025 à 18:14, il y a 13 heures 40 minutes Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 05/12/2025 à 02:35, il y a 5 heures 20 minutes Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 01:00, il y a 6 heures 55 minutes BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 50 minutes BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 55 minutes NXT Energy Solutions Completes Data Acquisition for SFD Survey
Publié le 05/12/2025 à 07:00, il y a 54 minutes Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 24 minutes CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 8 heures 4 minutes EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 29 minutes Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 39 minutes Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
